Status:
TERMINATED
The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)
Lead Sponsor:
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Conditions:
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Eligibility:
MALE
Brief Summary
The role of WB-MRI in the evaluation of prostate cancer patients treated with Lu-PSMA
Detailed Description
Multicentric, observational, single arm, prospective, study. All patients will undergo imaging assessments according to clinical practice or to Lu-PSMA Tumor Institute of Romagna (IRST) 185.03 protoc...
Eligibility Criteria
Inclusion
- \- Patients with mCRPC enrolled in the Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol, performing baseline CT and WB-MRI examinations and at least one CT and WB-MRI re-evaluation.
Exclusion
- no exclusion criteria
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 8 2022
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT05208229
Start Date
February 1 2021
End Date
March 8 2022
Last Update
April 1 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST s.r.l.
Meldola, Forlì-Cesena, Italy, 47014
2
European Institute of Oncology
Milan, Italy